TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR CO-AGONIST FOR THE TREATMENT OF TYPE 2 DIABETES WITH UNMATCHED EFFECTIVENESS REGRADING GLYCAEMIC CONTROL AND BODY WEIGHT REDUCTION